Spiderwort Biotech receives Health Canada Investigational Testing Authorization for CelluJuve®

OBIO NewsOntario Industry Updates
Written By Arsheen Kaur

Spiderwort Biotechnologies Inc., a pioneering biotechnology company focused on cellulose-based regenerative medicine, recently announced it has received Investigational Testing Authorization (ITA) from Health Canada for CelluJuve®, its next-generation cellulose-based dermal filler currently under development. The ITA enables Spiderwort Biotechnologies to initiate a human clinical trial in Canada to evaluate the safety and performance of CelluJuve® for tissue augmentation and rejuvenation.

Spiderwort is an OBIO® member, an alumnus of our BDSP™, CAAP®, H2BB™, HealthMINT™ and WiHI programs, and presented at the OBIO® Investment Summit.

Arsheen Kaur
Previous

OBIO® x CATTI's biomanufacturing initiative featured in BIOTECanada's INSIGHTS magazine
Next

Hyivy Health spotlighted in this feature by the Canadian Medical Association